• Citer

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.

par Schöffski, Patrick;Awada, Ahmad ;Dumez, Herlinde;Gil, Thierry ;Bartholomeus, Sylvie;Wolter, P;Taton, Martine ;Fritsch, Holger;Glomb, Patricia;Munzert, Gerd
Référence European journal of cancer, 48, 2, page (179-186)
Publication Publié, 2012-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.
Auteur:	Schöffski, Patrick; Awada, Ahmad; Dumez, Herlinde; Gil, Thierry; Bartholomeus, Sylvie; Wolter, P; Taton, Martine; Fritsch, Holger; Glomb, Patricia; Munzert, Gerd
Informations sur la publication:	European journal of cancer, 48, 2, page (179-186)
Statut de publication:	Publié, 2012-01
Sujet CREF:	Cancérologie
Mots-clés:	Dose escalation
	Phase I
	Polo-like kinase (Plk) inhibitor
	Solid tumours
	Volasertib (BI 6727)
MeSH keywords:	Adult
	Aged
	Antineoplastic Agents -- pharmacokinetics -- therapeutic use
	Cohort Studies
	Dose-Response Relationship, Drug
	Female
	Half-Life
	Humans
	Male
	Middle Aged
	Neoplasms -- drug therapy -- metabolism
	Protein Kinase Inhibitors -- pharmacokinetics -- therapeutic use
	Pteridines -- pharmacokinetics -- therapeutic use
	Young Adult
Note générale:	Clinical Trial, Phase I
	Journal Article
	Research Support, Non-U.S. Gov't
	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0959-8049
	info:doi/10.1016/j.ejca.2011.11.001
	info:pii/S0959-8049(11)00874-4
	info:scp/84655164874
	info:pmid/22119200